A Multidisciplinary Approach to Non-Melanoma Skin Cancer Conference


Friday, September 14, 2018

The incidence of non-melanoma skin cancer (NMSC) in the United States has been increasing for the past several decades with current estimates of approximately 9,500 new cases every day. Non-melanoma skin tumors represent the largest category of malignancies of any organ system. In recent years, there have been significant advances in the management of these tumors with higher grade/stage tumors requiring a multidisciplinary approach. This conference will focus on the diagnosis and management of some NMSC tumors.

Download agenda

Target Audience

This conference is intended for physicians, nurse practitioners, physician assistants, nurses, residents, fellows, and students who are involved in the diagnosis and treatment of patients with non-melanoma skin cancer.

Conference Objectives

At the conclusion of the conference, participants should be better able to:

  1. Define criteria for diagnosing squamous cell carcinoma, basal cell carcinoma, Merkel cell carcinoma, and CD30-positive T-cell lymphoma
  2. Explain criteria for different surgical options and review outcomes
  3. Describe criteria and outcomes for the use of radiation therapy
  4. Recite criteria, options, and outcomes for the use of chemotherapy

Continuing Education Credit

The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This live activity is sponsored by the UNMC Department of Pathology & Microbiology, Regional Pathology Services, and Nebraska Medicine Cancer Service Line, through the resources of the UNMC Center for Continuing Education.